Table 1.
Prevalence of adverse drug reactions (ADR) according to age, sex, and weight and HAART regimen
| N | ADR% prevalence (95% CI) | Odd ratio (95% CI) | P-value | |
|---|---|---|---|---|
| Age group, years | ||||
| <25 | 4 | 25.0 (24.2 – 74.0) | 1.0 | †p=0.86 |
| 25 – 34 | 53 | 20.7 (9.7 – 31.8) | 0.8 (0.1 – 8.3) | |
| 35 – 44 | 133 | 17.3 (10.8 -23.8) | 0.6 (0.1 – 6.3) | |
| 45 – 54 | 81 | 18.5 (10.0 – 27.1) | 0.7 (0.1 – 7.0) | |
| >55 | 68 | 23.5 (13.3 – 33.7) | 0.9 (0.1 – 9.5) | |
| Sex | ||||
| Male | 135 | 16.3 (10.0 – 22.6) | 1.0 | P=0.23 |
| Female | 204 | 21.6 (15.9 – 27.2) | 1.4 (0.8 – 2.4) | |
| Weight (kg) | ||||
| <60 | 100 | 22.0 (13.8 – 30.2) | 1.0 | P =0.4 |
| >60 | 239 | 18.4 (13.5 – 23.4) | 0.8 (0.5 – 1.4) | |
| HAART Regimen | ||||
| AZT-3TC-NVP | 102 | 10.8 (4.7 – 16.9) | 1.0 | P=0.01 |
| AZT-3TC-EFV | 94 | 16.0 (8.5 – 23.4) | 1.6 (0.7 – 3.6) | |
| D4T-3TC-NVP | 99 | 29.3 (20.3 – 38.3) | 3.4 (1.6 – 7.3) | |
| D4T-3TC-EFV | 27 | 29.6 (12.0 – 47.2) | 3.5 (1.2 – 9.8) | |
| Other | 17 | 17.6 (1.0 – 36.4) | 1.8 (0.4 – 7.2) | |
| Total | 339 | 19.5 (15.2 – 23.7) | - |
AZT: Zidovudine, NVP: Nevirapine, EFV: Effavirenz, 3TC: Lamivudine, D4T: Stavudine.
†
P-value for trend